13F HOLDINGS REPORT
Aisling Capital Management LP
Quarter ended Q3 2023 · Filed August 11, 2023 · Accession 0001766721-23-000003
Total Value
$204.1M
Positions
16
Other Managers
0
Confidential Omitted
No
Holdings (16)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | BridgeBio Pharma Inc. (BBIO) | BBIO | 6,068,125 | $104.4M | 51.13% |
| 2 | Verona Pharma plc (VRNA) | 925050106 | 1,115,352 | $23.6M | 11.55% |
| 3 | Syndax Pharmaceuticals, Inc. (SNDX) | SNDX | 1,025,000 | $21.5M | 10.51% |
| 4 | Biomea Fusion Inc (BMEA) | BMEA | 798,757 | $17.5M | 8.59% |
| 5 | Monte Rosa Therapeutics Inc (GLUE) | GLUE | 1,472,331 | $10.1M | 4.94% |
| 6 | Reneo Pharmaceuticals Inc (RPHM) | 75974E103 | 886,075 | $5.8M | 2.85% |
| 7 | Nuvation Bio Inc. (NUVB) | NUVB | 2,541,009 | $4.6M | 2.24% |
| 8 | Aclaris Theraputics Inc (ACRS) | ACRS | 434,455 | $4.5M | 2.21% |
| 9 | Elevation Oncology Inc (ELEV) | 28623U101 | 2,834,910 | $4.3M | 2.11% |
| 10 | Spruce Biosciences, Inc. (SPRB) | SPRB | 1,205,511 | $2.6M | 1.27% |
| 11 | Poseida Therapeutics Inc. (PSTX) | 73730P108 | 1,043,267 | $1.8M | 0.90% |
| 12 | Marker Therapeutics, Inc. (MRKR) | MRKR | 314,286 | $974,286 | 0.48% |
| 13 | Avrobio, Inc. (AVRO) | 05455M100 | 1,009,779 | $959,391 | 0.47% |
| 14 | Aeglea Biotherapeutics Inc (AGLE) | 00773J103 | 1,691,151 | $761,864 | 0.37% |
| 15 | Viracta Therapeutics Inc (VIRX) | 92765F108 | 288,571 | $406,885 | 0.20% |
| 16 | Atreca Inc. (BCEL) | 04965G109 | 387,653 | $379,900 | 0.19% |